https://ogma.newcastle.edu.au/vital/access/ /manager/Index ${session.getAttribute("locale")} 5 Risk of secondary progressive multiple sclerosis: a longitudinal study https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:38068 p <0.001), longer disease duration (HR=1.01, p=0.038), a higher Expanded Disability Status Scale score (HR=1.30, p<0.001), more rapid disability trajectory (HR=2.82, p<0.001) and greater number of relapses in the previous year (HR=1.07, p=0.010) were independently associated with an increased risk of secondary progressive multiple sclerosis. Improving disability (HR=0.62, p=0.039) and disease-modifying therapy exposure (HR=0.71, p=0.007) were associated with a lower risk. Recent cerebral magnetic resonance imaging activity, evidence of spinal cord lesions and oligoclonal bands in the cerebrospinal fluid were not associated with the risk of conversion. Conclusion:Risk of secondary progressive multiple sclerosis increases with age, duration of illness and worsening disability and decreases with improving disability. Therapy may delay the onset of secondary progression.]]> Wed 24 May 2023 12:22:34 AEST ]]> A plain language summary on the effectiveness of cladribine tablets compared with other oral treatments for multiple sclerosis: results from the MSBase registry https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:51433 Wed 22 May 2024 15:28:13 AEST ]]> The risk of secondary progressive multiple sclerosis is geographically determined but modifiable https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:54611 Wed 06 Mar 2024 10:38:32 AEDT ]]> Disability outcomes of early cerebellar and brainstem symptoms in multiple sclerosis https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:49895 Tue 13 Jun 2023 15:49:48 AEST ]]> Comparative effectiveness in multiple sclerosis: A methodological comparison https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:51624 Tue 12 Sep 2023 14:37:58 AEST ]]> Effectiveness of multiple disease-modifying therapies in relapsing-remitting multiple sclerosis: causal inference to emulate a multiarm randomised trial https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:53990 Thu 25 Jan 2024 13:04:15 AEDT ]]> Predictors of treatment switching in the Big Multiple Sclerosis Data Network https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:54767 Mon 11 Mar 2024 15:00:30 AEDT ]]> Comparative effectiveness of cladribine tablets versus other oral disease-modifying treatments for multiple sclerosis: Results from MSBase registry https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:51882 Fri 22 Sep 2023 09:08:11 AEST ]]> Disability accrual in primary and secondary progressive multiple sclerosis https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:51685 Fri 15 Sep 2023 09:36:29 AEST ]]> Variability of the response to immunotherapy among subgroups of patients with multiple sclerosis https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:51340 Fri 01 Sep 2023 13:35:50 AEST ]]>